Atugen Signs RNAi Deal with Aventis

Sep 13, 2004

NEW YORK, Sept. 13 (GenomeWeb News) - Atugen said today that it has formed a collaboration with Aventis to identify siRNA compounds that have potential for development as therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

IBM, Broad to Map Human Microbiome on World Community Grid
iCubate Receives CE Mark for Dx Platform, Bloodstream Infection Assay
Caprion Collaborating with FNIH on Alzheimer's Biomarkers
Jennifer Doudna, Feng Zhang Awarded NHGRI Grants for CRISPR-Based Research
BRCA1/2 LOH Testing May Offer Treatment Response Clues in Some Cancer Cases
Mass General, CRISPR Therapeutics to Develop Cancer Therapies

The Scan

Spiders and Scorpions, Oh My!

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

Keep It Secret

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Page Joins Chronic Disease Startup

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

This Week in Cell

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

Main menu